Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b multicenter single-arm study of UGN-102 for low-grade non-muscle invasive bladder cancer at intermediate risk of recurrence
MOH_2018-10-11_003694Phase 2Active, not recruiting
- Sponsor
- UroGen Pharma
- Start
- Nov 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zusduri in bladder cancer, transitional cell carcinoma (TCC) and non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Started Nov 2018; status: active, not recruiting.
02
Drugs
zusduri
03
Conditions
bladder cancertransitional cell carcinoma (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2018-10-11_003694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-11_003694.